Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyperAcute-Renal Immunotherapy in Metastatic Renal Cell Cancer
NCT02035358Phase 1Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- May 2015
- Primary completion
- Jan 2017
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HyperAcute-Renal in renal cell carcinoma (RCC), sponsored by Lumos Pharma, Inc. Primary endpoint: Percentage of patients with adverse events at 3 months. Started May 2015; status: completed.
02
Drugs
HyperAcute-Renal
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02035358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035358.